Targeting PRMT9 overcomes venetoclax resistance in AML by modulating splicing and inhibiting translation. Li Y, He X, Zhang L, Dong H, et al. Blood 2026;148:1328-1343.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li Y, He X, Zhang L, Dong H, et al. Targeting PRMT9 overcomes venetoclax resistance in AML by modulating splicing and inhibiting translation. Blood 2026;148:1328-1343.
PMID: 42118690